A detailed history of Herold Advisors, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Herold Advisors, Inc. holds 36,397 shares of BMY stock, worth $2.1 Million. This represents 0.42% of its overall portfolio holdings.

Number of Shares
36,397
Previous 34,442 5.68%
Holding current value
$2.1 Million
Previous $1.43 Million 31.68%
% of portfolio
0.42%
Previous 0.34%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $77,535 - $101,171
1,955 Added 5.68%
36,397 $1.88 Million
Q2 2024

Jul 24, 2024

BUY
$40.25 - $52.99 $61,542 - $81,021
1,529 Added 4.65%
34,442 $1.43 Million
Q1 2024

May 10, 2024

BUY
$47.98 - $54.4 $56,088 - $63,593
1,169 Added 3.68%
32,913 $1.78 Million
Q4 2023

Feb 02, 2024

SELL
$48.48 - $57.85 $93,275 - $111,303
-1,924 Reduced 5.71%
31,744 $1.63 Million
Q3 2023

Nov 08, 2023

BUY
$57.89 - $64.73 $60,842 - $68,031
1,051 Added 3.22%
33,668 $1.95 Million
Q2 2023

Jul 14, 2023

SELL
$63.71 - $70.74 $41,793 - $46,405
-656 Reduced 1.97%
32,617 $2.09 Million
Q1 2023

Apr 19, 2023

BUY
$65.71 - $74.53 $60,847 - $69,014
926 Added 2.86%
33,273 $2.31 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $172,843 - $204,671
2,524 Added 8.46%
32,347 $2.33 Million
Q3 2022

Nov 08, 2022

SELL
$0.13 - $76.84 $16 - $9,758
-127 Reduced 0.42%
29,823 $2.12 Million
Q2 2022

Jul 15, 2022

SELL
$72.62 - $79.98 $14,306 - $15,756
-197 Reduced 0.65%
29,950 $2.31 Million
Q1 2022

May 09, 2022

BUY
$61.48 - $73.72 $25,821 - $30,962
420 Added 1.41%
30,147 $2.2 Million
Q4 2021

Jan 20, 2022

BUY
$53.63 - $62.52 $142,334 - $165,928
2,654 Added 9.8%
29,727 $1.85 Million
Q3 2021

Nov 03, 2021

BUY
$59.17 - $69.31 $1.6 Million - $1.88 Million
27,073 New
27,073 $1.6 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Herold Advisors, Inc. Portfolio

Follow Herold Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Herold Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Herold Advisors, Inc. with notifications on news.